羟氯喹与 COVID-19 ：一个警示故事。
The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale.
机构信息
New York Medical College, Valhalla, New York (N.W.S.).
出版信息
Ann Intern Med. 2020 Oct 20;173(8):662-663. doi: 10.7326/M20-5041. Epub 2020 Jul 16.
Abstract
In their article, Skipper and colleagues report the results of trial of hydroxychloroquine for patients presenting with nonsevere COVID-19. The editorialists discuss the findings and the need to examine carefully not only what we know about hydroxychloroquine and COVID-19 but also how we learned it, disseminated it, and put it into practice.
摘要
在他们的文章中，Skipper 及其同事报告了羟氯喹治疗非重症 COVID-19 患者的试验结果。社论作者讨论了这些发现，并指出不仅需要仔细研究我们对羟氯喹和 COVID-19 的了解，还需要研究我们如何了解它、传播它以及将其付诸实践。
相似文献
1
The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale.羟氯喹与 COVID-19 ：一个警示故事。
Ann Intern Med. 2020 Oct 20;173(8):662-663. doi: 10.7326/M20-5041. Epub 2020 Jul 16.
2
QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.在新冠肺炎患者使用羟氯喹和/或阿奇霉素期间控制QT间期以预防尖端扭转型室速
Arq Bras Cardiol. 2020 Jun;114(6):1061-1066. doi: 10.36660/abc.20200389. Epub 2020 Jul 3.
3
Regulators split on antimalarials for COVID-19.监管机构在用于治疗新冠肺炎的抗疟疾药物问题上存在分歧。
Lancet. 2020 Apr 11;395(10231):1179. doi: 10.1016/S0140-6736(20)30817-5.
4
Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given.用于治疗新冠肺炎的氯喹/羟氯喹引发室性心律失常的风险：是否应该使用该药？
Indian Heart J. 2020 Mar-Apr;72(2):131-132. doi: 10.1016/j.ihj.2020.04.006. Epub 2020 Apr 27.
5
Repurposing antimalarials and other drugs for COVID-19.将抗疟药及其他药物重新用于治疗新冠肺炎。
Travel Med Infect Dis. 2020 Mar-Apr;34:101658. doi: 10.1016/j.tmaid.2020.101658. Epub 2020 Apr 2.
6
The impact of hydroxychloroquine shortages on patients with dermatological conditions during COVID-19 pandemic.新冠疫情期间羟氯喹短缺对皮肤病患者的影响。
Dermatol Ther. 2020 Jul;33(4):e13524. doi: 10.1111/dth.13524. Epub 2020 Jun 5.
7
A Word of Caution in the Use of Hydroxychloroquine in the Elderly COVID-19 Population.老年 COVID-19 患者使用羟氯喹的注意事项
Asia Pac J Ophthalmol (Phila). 2020 Jul-Aug;9(4):374-375. doi: 10.1097/APO.0000000000000314.
8
Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.氯喹和羟氯喹在2019冠状病毒病中的应用及其心血管影响：理解安全性差异以改进临床试验的解读与设计
Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008688. doi: 10.1161/CIRCEP.120.008688. Epub 2020 May 21.
9
Chloroquine and Hydroxychloroquine in COVID-19: Challenges and the Need for Caution in Low-Resource Settings.氯喹和羟氯喹在2019冠状病毒病中的应用：资源匮乏地区面临的挑战及谨慎使用的必要性
J Coll Physicians Surg Pak. 2020 Jun;30(6):78. doi: 10.29271/jcpsp.2020.Supp1.S78.
10
World War against COVID-19: How strong is our armamentarium?抗击新冠疫情之战：我们的武器库有多强大？
Med J Malaysia. 2020 May;75(3):314-315.
引用本文的文献
1
Preparing for pandemics: a systematic review of pandemic influenza clinical management guidelines.应对大流行的准备：大流行性流感临床管理指南的系统评价。
BMC Med. 2022 Nov 7;20(1):425. doi: 10.1186/s12916-022-02616-6.
2
Concerning Pathophysiology and Justifying Clinical Trials.关于病理生理学及临床试验的合理性
Am J Med. 2021 Jul;134(7):e439. doi: 10.1016/j.amjmed.2021.02.022.
3
[Reply to the letter «Evidence of effectiveness in the pharmacological management of patients withCOVID-19»].[对信件《2019冠状病毒病患者药物治疗有效性的证据》的回复]
Semergen. 2021 May-Jun;47(4):281. doi: 10.1016/j.semerg.2021.02.003. Epub 2021 Apr 14.
4
Viral Clearance and Serological Response to SARS-CoV-2 in Kidney Transplant Recipients.肾移植受者对 SARS-CoV-2 的病毒清除和血清学反应。
Transplant Proc. 2021 May;53(4):1180-1186. doi: 10.1016/j.transproceed.2020.11.008. Epub 2020 Dec 17.
5
Rise and Fall: Hydroxychloroquine and COVID-19 Global Trends: Interest, Political Influence, and Potential Implications.兴衰：羟氯喹与新冠疫情全球趋势：关注度、政治影响及潜在影响
ACR Open Rheumatol. 2020 Dec;2(12):760-766. doi: 10.1002/acr2.11207. Epub 2020 Dec 2.
本文引用的文献
1
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial.羟氯喹治疗非住院的 COVID-19 轻症成年患者：一项随机试验。
Ann Intern Med. 2020 Oct 20;173(8):623-631. doi: 10.7326/M20-4207. Epub 2020 Jul 16.
2
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.羟氯喹作为 COVID-19 暴露后预防的随机试验。
N Engl J Med. 2020 Aug 6;383(6):517-525. doi: 10.1056/NEJMoa2016638. Epub 2020 Jun 3.
3
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.羟氯喹治疗主要为轻症和中症的 2019 冠状病毒病患者：开放标签、随机对照试验。
BMJ. 2020 May 14;369:m1849. doi: 10.1136/bmj.m1849.
4
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.纽约州 COVID-19 患者住院死亡率与羟氯喹或阿奇霉素治疗的关联。
JAMA. 2020 Jun 23;323(24):2493-2502. doi: 10.1001/jama.2020.8630.
5
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的观察性研究。
N Engl J Med. 2020 Jun 18;382(25):2411-2418. doi: 10.1056/NEJMoa2012410. Epub 2020 May 7.
6
Against pandemic research exceptionalism.反对大流行研究例外论。
Science. 2020 May 1;368(6490):476-477. doi: 10.1126/science.abc1731. Epub 2020 Apr 23.
7
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
Zotero 插件